November 29, 2021
A Kentucky federal judge on Monday denied a bid to dismiss UCB’s suit against Catalent Pharma Solutions over its importation of the active ingredient in anti-epileptic drug Vimpat, saying the complaint plausibly alleges infringement.
May 13, 2021
A Kentucky federal judge refused to block Catalent Pharma Solutions Inc. from importing a key ingredient of the anti-epileptic drug Vimpat, saying the company is protected by a safe harbor provision of the Hatch-Waxman Act.
February 08, 2021
The company that makes the anti-epileptic drug Vimpat has lodged a patent lawsuit against Catalent Pharma Solutions Inc. over allegations that it imported several shipments of a key ingredient to help an Indian drugmaker evade an injunction in an earlier case.